scholarly journals Long term protective level of hepatitis B antibody after revaccination in liver transplanted children: an open-label randomized control trial study

2021 ◽  
Vol 35 (1) ◽  
pp. S141-S141
Author(s):  
Palittiya Sintusek ◽  
Yong Poovorawan ◽  
Supranee Buranapraditkun ◽  
Piyaporn Wanawongsawad ◽  
Ai-lada Intrarakamhang
Keyword(s):  
Hepatitis B ◽  
Randomized Control Trial ◽  
Protective Level ◽  
Open Label ◽  
Randomized Control

scholarly journals Effect of pentoxifylline on histological activity and fibrosis of nonalcoholic steatohepatitis patients: A one year randomized control trial

2017 ◽  
Vol 5 (3) ◽  
pp. 155-163 ◽  
Author(s):  
Shahinul Alam ◽  
SKM Nazmul Hasan ◽  
Golam Mustafa ◽  
Mahabubul Alam ◽  
Mohammad Kamal ◽  
...  
Keyword(s):  
Fatty Liver ◽  
Nonalcoholic Steatohepatitis ◽  
Randomized Control Trial ◽  
Lifestyle Modification ◽  
Control Group ◽  
Open Label ◽  
Histological Activity ◽  
Randomized Control ◽  
One Year ◽  
Lobular Inflammation

AbstractBackground and ObjectivesTo observe the effect of Pentoxifylline for 1 year on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis (NASH).Materials and MethodsA single center, open label Randomized Control Trial. Patients were included if they had ultrasonographic evidence of fatty liver and nonalcoholic fatty liver disease activity score (NAS) ≥ 5 on liver histology. A total of 35 patients were selected; 25 of PL (Experimental) group and 10 of L (Control) group. PL group received 400 mg pentoxifylline thrice daily along with lifestyle modification and there was only lifestyle modification for the L group. After one year, NAS and fibrosis was compared in both groups.ResultsIn PL group, NAS improved 2.10 ± 1.07; whereas in L group, NAS was 0.90 ± 0.99 (P = 0.006). As per the protocol analysis, NAS ≥ 2 improved in 15/20 (75%) in PL group and in 3/10 (30%) in L group (P = 0.018). In PL group, the individual component of NAS, steatosis improved from 2.30 ± 0.66 to 0.95 ± 0.76 (P = 0.000), lobular inflammation from 1.65 ± 0.59 to 1.05 ± 0.51 (P = 0.002) and hepatocyte ballooning from 1.50 ± 0.51 to 1.30 ± 0.57 (P = 0.258). In L group, steatosis improved from 2.30 ± 0.68 to 1.40 ± 1.08 (P = 0.01), lobular inflammation and hepatocyte ballooning did not improve. The fibrosis score did not improve in any group. In PL group, NAS improved significantly (P = 0.027; OR=22.76, CI=1.43-362.40) independent of weight reduction.ConclusionPentoxifylline for 1 year improves the hepatic histological activity but not fibrosis of NASH patients.

scholarly journals HomeStyles: Strategies Used to Retain Parents of Preschool Children in a Long‐Term Randomized Control Trial

2016 ◽  
Vol 30 (S1) ◽  
Author(s):  
Colleen Delaney ◽  
Jennifer T Martin‐Biggers ◽  
Mallory Koenings ◽  
Rebecca Tonnessen ◽  
Carol Byrd‐Bredbenner
Keyword(s):  
Preschool Children ◽  
Randomized Control Trial ◽  
Randomized Control

scholarly journals The Vaccine Coverage and Vaccine Immunity Status and Risk Factors of Non-Protective Levels of Antibodies Against Vaccines in Children with Juvenile Idiopathic Arthritis: Russian Tertiary Centre Study.

2021 ◽  
Author(s):  
Mikhail Kostik ◽  
Natalia A. Lubimova ◽  
Irina V. Fridman ◽  
Olga V. Goleva ◽  
Susanna M. Kharit
Keyword(s):  
Risk Factors ◽  
Hepatitis B ◽  
Vaccine Coverage ◽  
Immunosuppressive Drugs ◽  
Protective Level ◽  
Tertiary Centre ◽  
Methotrexate Treatment ◽  
Systemic Arthritis ◽  
Vaccine Immunity

Abstract Background: Immunosuppressive drugs, decreased vaccine coverage, aberrant immunity might be factors of low anti-vaccine antibodies in JIA patients. The study aimed to evaluate vaccine coverage, post-vaccine immunity and risk factors of non-protective levels of antibodies against measles, mumps, rubella, hepatitis B and diphtheria in JIA patients. Methods: A prospective study included 170 children diagnosed with JIA aged 2 to 17 years, who received routine vaccinations against measles, rubella, mumps (MMR) diphtheria and hepatitis B. In all patients, the levels of post-vaccination antibodies (IgG) for measles, rubella, mumps, hepatitis B and diphtheria measured with ELISA.Results: Protective level of antibodies were 50% against hepatitis B, 52% - diphtheria, 58% - measles, 80% - mumps, 98% rubella. The best coverage for MMR had patients with enthesytis-related arthritis-85%, compare to oligoarthritis-70%, polyarthritis-69%, systemic arthritis-63%. Diphtheria coverage was 50%, 51%, 46%, 63%, respectively. Incomplete MMR vaccination had 39% patients, treated with biologics, 22% with methotrexate and 14% with NSAID (p=0.025), and 61%, 46%, 36% for diphtheria (p=0.021). Incomplete vaccination was a risk factor of non-protective level of antibodies against measles (HR=2.03 [95%CI: 1.02; 4.0], p=0.042), parotitis (HR=6.25 [95%CI: 2.13; 17.9], p=0.0008) and diphtheria (HR=2.39 [95%CI: 1.18; 4.85], p=0.016) vaccines, as well as JIA category, biologics, corticosteroids and long-term methotrexate treatment for distinct vaccines.Conclusion: Children with JIA may have lower anti-vaccine antibodies levels and required routine check, especially in children with incomplete vaccination, biologics, systemic arthritis and long-term methotrexate treatment.

Abstract P146: The PATIENT Study: Lessons Learned During the Development of a Multi-Site, Pragmatic Randomized Control Trial in a Large Health Maintenance Organization

Circulation ◽  
2012 ◽  
Vol 125 (suppl_10) ◽  
Author(s):  
Ashli Owen-Smith ◽  
Suma Vupputuri ◽  
Cynthia Rand ◽  
Jeffrey Tom ◽  
Andrew Williams ◽  
...  
Keyword(s):  
Disease Management ◽  
Health Plan ◽  
Randomized Control Trial ◽  
Patient Adherence ◽  
Lessons Learned ◽  
Successful Implementation ◽  
Health Maintenance ◽  
Randomized Control ◽  
The Impact

Introduction: Patient adherence to chronic therapy is the necessary link between effective treatments and improved patient outcomes. However, the frequent failure of patients to adhere to long-term medication regimens is a challenge in chronic disease management. Though many prior interventions aimed at improving patient medication adherence have been successful, they are often costly and have limited disseminability. Methods: The PATIENT ( P romoting A dherence T o I mprove the E ffective n ess of CVD T herapies) study is a randomized control trial to compare the impact of two low-cost, low-intensity health information technology-based interventions (which include automated prescription refill reminder calls and mailed education materials) on patient adherence to selected chronic CVD medications. The primary goal throughout the development of this intervention was for it to be disseminable at the end of the grant period. We implemented several strategies aimed at increasing the likelihood of long-term implementation and dissemination of the intervention. These strategies included establishing an advisory board that included a diverse group of health plan clinicians and staff, conducting stakeholder interviews and participant focus groups, presenting at health plan meetings and carrying out a pilot of the intervention prior to the start of the main trial. Results: Our efforts in prioritizing the disseminability of the intervention highlighted several important lessons. First, it was important to develop all aspects of the intervention in partnership with health plan stakeholders, as their feedback was critical in the development of a protocol that would be ultimately congruent with local policies. Second, conversations with stakeholders highlighted the ways in which each of the sites were similar to and different from one another, thereby identifying which components of the intervention should be consistent across sites but also underscoring the need for there to be some regional customization. Preliminary results from the pilot of the intervention indicate that these efforts have been worthwhile: 62% of participants reported that the automated phone calls were helpful and the majority (80%) are willing to take a similar call in the future; similarly, the majority of participants reported that the mailed health education materials were useful (∼64%) and easy to understand (∼71%). Conclusions: The PATIENT intervention, if successful, could have significant public health applications as flexible and generalizable components of disease management programs. Understanding the barriers to and facilitators of successful implementation is critical to the widespread implementation of the intervention. Lessons learned from the developing and implementing the present study may aid others in similar efforts and in different settings.

Sign in / Sign up

Export Citation Format

Share Document